Nascent Biotech (NBIO) 10-Q 14 Feb 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Dec. 31, 2022	Feb. 14, 2023
Cover [Abstract]
Entity Registrant Name	NASCENT BIOTECH INC
Entity Central Index Key	0001622057
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		124,485,269
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-55299
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	46-5001940
Entity Address Address Line 1	631 US Hwy 1, Suite 407
Entity Address City Or Town	North Palm Beach
Entity Address State Or Province	FL
Entity Address Postal Zip Code	33408
City Area Code	612
Local Phone Number	961-5656
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Mar. 31, 2022
Current assets:
Cash	$ 558,761	$ 94,414
Prepaid	7,083	11,000
Total current assets	565,844	105,414
Total assets	565,844	105,414
Current liabilities:
Accounts payable and accrued liabilities	387,253	776,891
Convertible note- net of discount	470,171	0
Derivative liability	1,072,494	0
Total current liabilities	1,929,918	776,891
Total liabilities	1,929,918	776,891
Commitments and contingencies	0	0
Stockholders' deficit:
Preferred stock, $0.001 par value, 50,000,000 authorized, none issued and outstanding. respectively	0	0
Common stock, $0.001 par value; 500,000,000 authorized, 122,046,172 and 111,313,175 issued and outstanding, respectively	122,046	111,313
Additional paid-in capital	19,618,596	18,039,016
Accumulated deficit	(21,104,716)	(18,821,806)
Total stockholders' deficit	(1,364,074)	(671,476)
Total liabilities and stockholders' deficit	$ 565,844	$ 105,414

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Mar. 31, 2022
Stockholders deficit
Preferred stock shares par value	$ 0.001	$ 0.001
Preferred stock shares authorized	50,000,000	50,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	122,046,172	111,313,175
Common stock shares outstanding	122,046,172	111,313,175

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
License fee revenue	$ 0	$ 1,000,000	$ 0	$ 1,000,000
Operating expenses:
Consulting	246,590	108,000	883,655	388,813
General and administrative expense	132,934	70,538	324,623	313,536
Clinical trials	39,627	149,487	219,155	200,192
Research and development	55,875	41,000	188,503	139,531
Operating expense	(475,026)	(369,025)	(1,615,936)	(1,042,072)
Income (loss) from operations	(475,026)	630,975	(1,615,936)	(42,072)
Other income (expense):
Interest income	144	0	160	10
Gain on debt settlement	28,000	0	28,000	5,000
Change in fair value of derivative	258,462	57,703	634,118	373,585
Financing costs	0	0	(5,124)	(101,150)
Loss on original issuance discount	0	(86,314)	(329,390)	(287,979)
Interest expense	(648,900)	(5,041)	(994,738)	(11,177)
Total other income (expense)	(362,294)	(33,652)	(666,974)	(21,711)
Net income (loss) before taxes	(837,320)	597,323	(2,282,910)	(63,783)
Income tax	0	0	0	0
Net income (loss)	$ (837,320)	$ 597,323	$ (2,282,910)	$ (63,783)
Net income (loss) per share, basic	$ (0.01)	$ 0.01	$ (0.02)	$ 0
Net income (loss) per share - diluted	$ (0.01)	$ 0.01	$ (0.02)	$ 0
Weighted average number of shares outstanding, basic	119,500,985	107,728,175	115,398,628	107,471,003
Weighted average number of shares outstanding- diluted	119,500,985	112,358,175	115,398,628	107,471,003

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, amount at Mar. 31, 2021	$ (472,505)	$ 54	$ 104,834	$ 17,774,023	$ (18,351,416)
Balance, shares at Mar. 31, 2021		54,130	104,834,083
Common stock issued to related parties, shares			568,719
Common stock issued to related parties, amount	59,716	$ 0	$ 569	59,147	0
Common stock issued for service, shares			50,000
Common stock issued for service, amount	5,250	0	$ 50	5,200	0
Common stock issued for AP - related parties, shares			307,010
Common stock issued for AP - related parties, amount	23,332	$ 0	$ 307	23,025	0
Common stock issued for preferred shares, shares		(54,130)	1,968,363
Common stock issued for preferred shares, amount	0	$ (54)	$ 1,968	(1,914)	0
Net loss	(450,076)	0	$ 0	0	(450,076)
Balance, shares at Jun. 30, 2021			107,728,175
Balance, amount at Jun. 30, 2021	(834,283)	0	$ 107,728	17,859,481	(18,801,492)
Balance, amount at Mar. 31, 2021	(472,505)	$ 54	$ 104,834	17,774,023	(18,351,416)
Balance, shares at Mar. 31, 2021		54,130	104,834,083
Net loss	(63,783)
Balance, shares at Dec. 31, 2021			107,728,175
Balance, amount at Dec. 31, 2021	(447,990)	$ 0	$ 107,728	17,859,481	(18,415,199)
Balance, amount at Jun. 30, 2021	(834,283)	0	$ 107,728	17,859,481	(18,801,492)
Balance, shares at Jun. 30, 2021			107,728,175
Net loss	(211,030)		$ 0	0	(211,030)
Balance, shares at Sep. 30, 2021			107,728,175
Balance, amount at Sep. 30, 2021	(1,045,313)	0	$ 107,728	17,859,481	(19,012,522)
Net loss	597,323		$ 0	0	597,323
Balance, shares at Dec. 31, 2021			107,728,175
Balance, amount at Dec. 31, 2021	(447,990)	0	$ 107,728	17,859,481	(18,415,199)
Balance, amount at Mar. 31, 2022	(671,476)	0	$ 111,313	18,039,016	(18,821,806)
Balance, shares at Mar. 31, 2022			111,313,175
Common stock issued to related parties, shares			1,052,500
Common stock issued to related parties, amount	305,224	0	$ 1,052	304,172	0
Common stock issued for service, shares			1,000,000
Common stock issued for service, amount	60,000	0	$ 1,000	59,000	0
Net loss	(1,299,876)	0	$ 0	0	(1,299,876)
Common stock issued for warrant exercise, shares			3,700,000
Common stock issued for warrant exercise, amount	148,000	0	$ 3,700	144,300	0
Warrants issued with convertible notes	21,336	0	$ 0	21,336	0
Balance, shares at Jun. 30, 2022			117,065,675
Balance, amount at Jun. 30, 2022	(1,436,792)	0	$ 117,065	18,567,825	(20,121,682)
Balance, amount at Mar. 31, 2022	(671,476)	0	$ 111,313	18,039,016	(18,821,806)
Balance, shares at Mar. 31, 2022			111,313,175
Net loss	$ (2,282,910)
Common stock issued for convertible debt, shares	9,275
Balance, shares at Dec. 31, 2022			122,046,172
Balance, amount at Dec. 31, 2022	$ (1,364,074)	0	$ 122,046	19,618,596	(21,104,716)
Balance, amount at Jun. 30, 2022	(1,436,792)	0	$ 117,065	18,567,825	(20,121,682)
Balance, shares at Jun. 30, 2022			117,065,675
Common stock issued to related parties, shares			212,629
Common stock issued to related parties, amount	65,916		$ 213	65,703	0
Common stock issued for service, amount	9,275		38	9,237	0
Net loss	(145,714)		$ 0	0	(145,714)
Common stock issued for warrant exercise, shares			500,000
Common stock issued for warrant exercise, amount	60,000		$ 500	59,500	0
Warrants issued with convertible notes	157,402		$ 0	157,402	0
Common stock issued for convertible debt, shares			379,080
Common stock issued for convertible debt, amount	101,973		$ 379	101,594	0
Common stock issued for AP, shares			37,700
Balance, shares at Sep. 30, 2022			118,195,084
Balance, amount at Sep. 30, 2022	(1,187,940)	0	$ 118,195	19,961,261	(20,267,396)
Common stock issued to related parties, shares			718,000
Common stock issued to related parties, amount	143,600	0	$ 718	142,882	0
Net loss	(837,320)	0	$ 0	0	(837,320)
Common stock issued for convertible debt, shares			3,133,088
Common stock issued for convertible debt, amount	454,594	0	$ 3,133	451,461	0
Stock option expense	62,992	0	$ 0	62,992	0
Balance, shares at Dec. 31, 2022			122,046,172
Balance, amount at Dec. 31, 2022	$ (1,364,074)	$ 0	$ 122,046	$ 19,618,596	$ (21,104,716)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,282,910)	$ (63,783)
Stock based compensation - related parties	514,740	59,716
Stock-based compensation	60,000	5,250
(Gain) loss in fair value of derivative liability	(634,118)	(373,585)
Debt discount amortization	962,257	287,979
Loss on notes	$ 286,265	0
Option expense	62,992
Changes in operating assets and liabilities:
Accounts payable and accrued expenses	$ (373,796)	154,891
Prepaid	3,917	0
Due to related parties	0	50,335
Net cash provided by (used in) operating activities	(1,400,650)	120,803
Cash flows from financing activities:
Repayment of convertible notes	(275,000)	(320,500)
Proceeds from warrant exercise	208,000	0
Proceeds from convertible notes	1,932,000	200,000
Net cash provided (used) by financing activities	1,865,000	(120,500)
Net increase (decrease) in cash	464,350	303
Cash -beginning of year	94,414	1,434
Cash -end of period	558,764	1,737
SUPPLEMENT DISCLOSURES:
Interest paid	11,135	20,055
Income taxes paid	0	0
Non Cash Transactions
Common stock issued for conversion of preferred shares	0	1,968
Common stock issued for convertible debt	556,567	0
Common stock issued for accrued expenses- related party	0	23,332
Initial discount from derivatives	$ 178,739	$ 0
Common stock issued for AP	9,275

ORGANIZATION AND NATURE OF OPER

ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
	Dec. 31, 2022
ORGANIZATION AND NATURE OF OPERATIONS
ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc. (“Nascent” or the “Company”) was incorporated on March 3, 2014 under the laws of the State of Nevada. The Company is actively developing Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a phase 1 clinical trial biopharmaceutical company that focuses on biologic drug candidates that are preparing for initial clinical testing for the treatment of brain and pancreatic cancer. On March 31, 2017, the Company filed its IND submission with the United States Food and Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018, the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trials. On March 15, 2021, the Company opened phase1 clinical trials. As of December 31, 2022, the Company had completed dosing of patients in the last cohort of the phase 1 clinical trials. The company is in the process of completing the required protocol and submitting the data to the FDA for approval to commence phase 2 clinical trials. On November 8, 2022 the Company was granted patient No. 11.492,394 from the Untied States Patient and Trademark Office for the patient entitled “Kits and Containers for Treating Vimentin Expressing Tumors.” This is the second patient issued in favor of the Company for Pritumumab.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Dec. 31, 2022
BASIS OF PRESENTATION
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles. The Company has elected a fiscal year ending on March 31. The accompanying unaudited interim consolidated financial statements of the Company for the three and nine months ended December 31, 2022 and 2021 have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information in accordance with Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended March 31, 2022. In the opinion of management, the unaudited financial statements have been prepared on the same basis as the annual financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial position and the results of operations for the interim periods presented herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for any subsequent quarters or for an entire year. Basis of Presentation The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the Black-Scholes pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material. Revenue recognition In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which are the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. During the nine months period ended December 31, 2022, no revenue was received. Accounts receivable Accounts receivables are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the three and nine months ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company did not have any accounts receivable.

GOING CONCERN

GOING CONCERN	9 Months Ended
	Dec. 31, 2022
GOING CONCERN
GOING CONCERN	NOTE 3 - GOING CONCERN The Company’s consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has a working capital deficit and has incurred losses from operations. The Company has no revenue to cover its operating costs and the Company will incur additional expenses in the future developing their product. These factors raise substantial doubt about the company’s ability to continue as a going concern. The Company engages in research and development activities that must be satisfied in cash secured through outside funding. The Company may offer noncash consideration and seek equity lines as a means of financing its operations. If the Company is unable to obtain revenue producing contracts or financing or if the revenue or financing it does obtain is insufficient to cover any operating losses it may incur, it may substantially curtail or terminate its operations or seek other business opportunities through strategic alliances, acquisitions or other arrangements that may dilute the interests of existing stockholders. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Dec. 31, 2022
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 4 - RELATED PARTY TRANSACTIONS On September 1, 2015, the Company entered five-year employment contracts with three of its officers and directors. One of the officers and director resigned as of September 30, 2020. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company as of the date of the contracts. As additional future shares are issued, the officers and directors are entitled to additional shares, so their aggregate ownership percentage initially remained at 11% (undated to 18% as noted below) of the outstanding shares of the Company. The agreements were amended on September 1, 2020, as noted below, and the table reflects the amendment to these agreements. The following table sets forth the shares earned under these contracts for the two active officers as of December 31, 2022: Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 8,890,269 9,919,179 Chief Financial Officer 617,346 4,677,723 5,295,069 Total 1,646,256 13,567,992 15,214,248 On September 1, 2020, the Company entered five-year compensation agreements with two of its officers and directors. Under the terms of the agreements the Company issued shares of common stock to the two senior officers equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers are entitled to additional future shares, so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company. Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Total $ 430,000 During the nine months ended December 31, 2022, two officers and a director were issued 1,983,129 shares of common stock with a value of $514,740 for service.

EQUITY

EQUITY	9 Months Ended
	Dec. 31, 2022
EQUITY
EQUITY	NOTE 5 - EQUITY Preferred On April 1, 2021, 54,130 shares of preferred stock were converted into 1,968,363 shares of common stock. The conversion eliminated all outstanding convertible preferred shares. Common During the nine months ended December 31, 2021, three officers and directors were issued 568,719 shares of common stock with a value of $59,716 for service. During the nine months period ended December 31, 2021 a director of the Company converted $23,332 of accrued compensation into 307,010 shares of common stock of the Company. During the nine months period ended December 31, 2021, the Company issued 50,000 shares of common stock with a value of $5,250 for service. During the nine months period ended December 31, 2021, 54,130 shares of preferred stock were converted into 1,968,363 shares of common stock. The conversion eliminated all outstanding convertible preferred shares. During the nine months ended December 31, 2022, two officers and a director were issued 1,983,129 shares of common stock with a value of $514,740 for service. During the nine months ended December 31, 2022, four entities were issued 4,200,000 shares of common stock with a value of $208,000 for the exercise of 3,700,000 warrants. During the nine months ended December 31, 2022, the Company issued 37,700 shares of common stock with a value of $9,275 for accounts payable. During the nine months ended December 31, 2022, the medical director was issued 1,000,000 shares of common stock with a value of $60,000 for service. During the nine months period ended December 31, 2022, the Company issued 3,512,168 shares of common stock with a value of $556,565 for the conversion of $550,000 of convertible notes and $6,565 in interest.

OPTIONS

OPTIONS	9 Months Ended
	Dec. 31, 2022
OPTIONS
OPTIONS	NOTE 6 - OPTIONS On November 17, 2022 the Company issued 500,000 options to one individual with an exercise price of $0.18 per share. The options have a 5 year life and vested 250,000 options at inception and 25,000 options per month thereafter until fully vested. The options were fair valued using a volatility of 250%, discount rate of 4.35% at $114,531 to be amortized over the 5 year period. As of December 31, 2022, the Company expensed $5,727 in options. The following sets forth the options granted and outstanding during the nine months ended December 31, 2022: Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2022 930,000 $ 0.34 3.80 930,000 $ - Granted 500,000 0.18 5.0 250,000 - Exercised - - - - - Outstanding at December 31, 2022 1,430,000 $ 0.28 4.06 1,180,000 $ 10,000 The weighted average remaining life and intrinsic value of the options as of December 31, 2022, was 4.06 years and zero, respectively.

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2022
WARRANTS
WARRANTS	NOTE 7 - WARRANTS During the year ended March 31, 2021 the Company issued 3,700,000 warrants and used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date, using the following key inputs: market prices of the Company’s common stock at dates of grant between $0.08-0.11 per share, conversion price of $0.15, volatility of 312.5%-314.49% and discount rate of 0.14-0.16%. Based on the fair value of the common stock of $437,000 and value of the warrants of $349,605 the fair value of the warrants was calculated to be 41% of the total value or $303,000. During the year ended March 31, 2021 the valuation resulted in a deemed dividend from the down round calculation of $555,000. As of December 31, 2022 3,700,000 warrants were converted into 3,700,000 shares of common stock for cash at a value for $148,000. On April 7, 2022, the Company issued 500,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.08 per share, conversion price of $0.12 per share, volatility of 132% and discount of 1.78%. The fair value of the warrants were calculated to be $ 26,000 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $21,336 is accounted for as paid in capital. As of December 31, 2022 the 500,000 warrants were converted into 500,000 shares of common stock with a value of $60,000. On August 31, 2022 the Company issued 750,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.41 per share, conversion price of $0.60 per share, volatility of 137% and discount of 3.50%. The fair value of the warrants were calculated to be $ 188,760 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $9,902 is accounted for as paid in capital. On September 2, 2022 the Company issued 250,000 warrants as part of a convertible note issued the same date. The Company used the Black Scholes Pricing model to estimate the fair value of the warrants as of grant date using the following key inputs; market prices of the Company’s stock at date of grant of $0.345 per share, conversion price of $0.60 per share, volatility of 137% and discount of 3.47%. The fair value of the warrants were calculated to be $50,273 and was used to allocate the proceeds to the two elements based on the relative fair value of the debt instruments without the warrants and of the warrants at the time of issuance. The portion of the proceeds were allocated to the warrants of $2,484 is accounted for as paid in capital. The weighted average remaining life and intrinsic value of the warrants as of December 31, 2022 was: Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2021 3,700,000 $ 0.15 2.00 $ - Granted - - - - Exercised - - - - Expired - - - - Outstanding at March 31, 2022 3,700,000 $ 0.15 1.35 $ - Granted 1,500,000 0.44 1.83 - Exercised (4,200,000 ) - - - Expired - - - - Outstanding as of December 31, 2022 1,000,000 $ 0.60 1.75 $ -

CONVERTIBLE DEBT

CONVERTIBLE DEBT	9 Months Ended
	Dec. 31, 2022
CONVERTIBLE DEBT
CONVERTIBLE DEBT	NOTE 8 - CONVERTIBLE DEBT On October 28, 2020, the Company issued a $138,000 convertible note with an OID of $10,000. The note matured on October 28,2021 with interest at 10% per annum. After 180 days the note was convertible into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years. On April 20, 2021 note was paid with the principal of $138,000, accrued interest of $6,805 and financing costs of $41,400. On November 11, 2020, the Company issued a $82,500 convertible note with an OID of $7,500. The note matured on October 28, 2021 with fixed interest of 10%. After 180 days the note was convertible into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion. On April 22, 2021, the note was paid consisting of principal of $82,500, accrued interest of $8,250 and finance costs of $24,750. On February 16, 2021, the Company issued a $100,000 convertible note with an OID of $5,000. The note matured on February 16, 2022, with fixed interest of 10%. After 180 days the note was convertible into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years. On August 16, 2021, the note was paid consisting of principal of $100,000, accrued interest of $5,000 and financing costs of $35,000. On August 10, 2021, the Company issued a $200,000 convertible note. The note matured on February 10, 2022, with fixed interest of 10%. Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note was convertible into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years. On March 28, 2022, the Note was paid consisting of $200,000 in principal, accrued interest of $9,973 and financing costs of $50,000. On April 7, 2022, the Company issued a $275,000 convertible note with an OID of $25,000. The note matures on March 29, 2023, bears fixed interest of 8% plus contains a most favored nations statement. Within 180 days of issuance, the note may be repaid at a premium of 115% of the face value of the note and 150% of the unconverted balance of the note after 180 days and prior to maturity. After 180 days the note may be converted into common stock of the Company at $0.075 per share or a 20% discount to the lowest VWAP (Volume- Weighted Average Pricing) price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years. On September 9, 2022 the note was paid with the note principal of $275,000, interest of $9,162 and premium of $42,624 for a total of $326,786. On August 31, 2022 the Company entered into an agreement with an unrelated third party for convertible debentures totaling $1,500,000. The first $500,000 was paid at closing with the second $500,000 paid on September 20, 2022, upon filing of an S-1 Registration, and the third $500,000 paid on September 27, 2022, upon the S-1 becoming effective. Each debenture matures one year from date of issuance. The interest rate for each debenture is six percent (6%) per annum and the Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value. The Company also issued a warrant to purchase 750,000 shares of the Company’s common stock for a period of two years, expiring on August 30, 2024, at an exercise price of $0.60 per share. As part of the agreement the Company filed an S-1 registration statement registering the underlying common shares for the debenture conversion and the warrants. The initial derivatives were calculated for each debenture as follows: 1. Debenture 1- risk free interest of 3.50%, volatility of 137% and expected life of 1.00 years 2. Debenture 2- risk free interest of 4.03%, volatility of 140% and expected life of 1.00 years 3. Debenture 3- risk free interest of 3.98%, volatility of 141% and expected life of 1.00 years During the nine months period ended December 31, 2022, the Company issued 2,524,629 shares of common stock with a value of $406,566 for the conversion of $400,000 of convertible note and $6,566 in interest, leaving a balance due of $1,100,000 of convertible notes plus accrued interest. On September 2, 2022 the Company entered into an agreement with an unrelated third party for convertible debentures totaling $500,000. The first $250,000 was paid at closing with the second $250,000 to be paid upon the S-1 becoming effective. Each debenture matures one year from date of issuance. The interest rate for each debenture is six percent (6%) per annum and the Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value. The Company also issued a warrant to purchase 250,000 shares of the Company’s common stock for a period of two years, expiring on August 30, 2024, at an exercise price of $0.60 per share. As part of the agreement the Company filed an S-1 registration statement registering the underlying common shares for the debenture conversion and the warrants. The initial derivative was calculated using risk free interest of 3.47%, volatility of 137% and expected life of 1 year. As of December 31, 2022 the funds for the second debenture had not been received. During the nine month period ended December 31, 2022 the Company issued 987,539 shares of common stock for the conversion of $150,000 of the convertible note leaving a balance of $100,000 plus accrued interest.

FAIR VALUE MEASUREMENTS AND DER

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	9 Months Ended
	Dec. 31, 2022
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES	NOTE 9 - FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES As defined in (Financial Accounting Standards Board ASC 820), fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilized the market data of similar entities in its industry or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. FASB ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities, and listed equities. Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options, and collars. Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value As December 31, 2022, the Company believes the amounts reported for cash, payables, accrued liabilities and amounts due to related parties approximate their fair values, due to the nature or duration of these instruments. The following table represents the change in the fair value of the derivative liabilities during the quarter ended December 31, 2022: Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2022 $ - $ - $ - Additions at fair value - - 1,706,612 Change in fair value of the derivative - - (634,118 ) Balance at December 31, 2022 $ - $ - $ 1,072,494 The estimated fair value of the derivative liabilities at December 31, 2022 was calculated using the Black Scholes pricing model with the following assumptions: Risk-free interest rate 4.73 % Expected life in years .67-.74 Dividend yield 0 % Expected volatility 135-163

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2022
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 10 –COMMITMENTS AND CONTINGENCIES On September 30, 2016, the Company entered a cell line sales agreement with the product manufacturer. Under the terms of the agreement the Company is obligated to make future payments based on the milestones of its achievements. These future payments may be as followed; 1. $100,000 upon the initiation (first dose/first patient) of the first Phase I clinical trial (or equivalent) of a Product; 2. $225,000 upon the initiation (first dose/first patient) of the first Phase III clinical trial (or equivalent) of a Product 3. $225,000 payable upon the first Biologics License Application approval (or equivalent) of a product. 4. Annual maintenance fee upon completion of phase I manufacturing or the transfer of the cell line from Catalent’s control of $50,000; 5. A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly. As of December 31, 2022, the Company paid the outstanding net balance of $325,000 due the manufacture for the balance of the annuals fees due and initiation of the phase 1 clinical trials payment. On March 9, 2020, the Board of Directors of the Company adapted an expense bonus program. Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocated 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors.

LICENSE AGREEMENT

LICENSE AGREEMENT	9 Months Ended
	Dec. 31, 2022
LICENSE AGREEMENT
LICENSE AGREEMENT	NOTE 11 - LICENSE AGREEMENT On March 31, 2021, the Company issued a license agreement for US $5,000,000 to BioRay Pharmaceutical Co, LTD, licensing Pritumumab internationally with the exclusion of North and Central America and the Caribbean Islands. Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials, which started in March 2021. In addition, the Company received $750,000 upon the enrollment of the 12th patient or the dosage level of 8.0 mg/kg, whichever was achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin. Upon commercialization by the Licensee, the Company will receive a 9% royalty on net sales for 20 years. As of December 31, 2022 the Company had received the three initial payments totaling $1,750,000.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Dec. 31, 2022
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 12 - SUBSEQUENT EVENTS On January 23, 2023 the Company issued 1,028,697 shares of common stock for the conversion of $100,000 of convertible debt and $1,841 in interest for a total value of $101,841. On February 9, 2023 the Company issued 1,410,400 shares of common stock for the conversion of $100,000 of convertible debt and $279 of interest for a total of $100,279. The Company has evaluated subsequent events to determine events occurring after December 31, 2022 through the date of this filing that would have a material impact on the Company’s financial results or require disclosure and have determined none exist other than those noted above in this footnote.

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Dec. 31, 2022
BASIS OF PRESENTATION
Basis of Presentation	The Company computes net loss per share in accordance with ASC 260, Earnings per Share We have identified the conversion features of certain of our convertible notes payable as derivatives. We estimate the fair value of the derivatives using the Black-Scholes pricing model. We estimate the fair value of the derivative liabilities at the inception of the financial instruments, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount, and a gain or loss on change in derivative liabilities as applicable. These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility and variable conversion prices based on market prices as defined in the respective agreements. These inputs are subject to significant changes from period to period and to management's judgment; therefore, the estimated fair value of the derivative liabilities will fluctuate from period to period, and the fluctuation may be material.
Revenue recognition	In April 2016, the FASB issued ASU 2016–10 Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing. The amendments in this Update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this Update clarify the following two aspects of Topic 606: identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas. Topic 606 includes implementation guidance on (a) contracts with customers to transfer goods and services in exchange for consideration and (b) determining whether an entity’s promise to grant a license provides a customer with either a right to use the entity’s intellectual property (which is satisfied at a point in time) or a right to access the entity’s intellectual property (which is satisfied over time). The amendments are intended to render more detailed implementation guidance with the expectation to reduce the degree of judgement necessary to comply with Topic 606. ASC Topic 606 prescribes a new five-step model entities should follow in order to recognize revenue in accordance with the core principle. These five steps are: 1. Identify the contract(s) with a customer. 2. Identify the performance obligations in the contract. 3. Determine the transaction price. 4. Allocate the transaction price to the performance obligations in the contract. 5. Recognize revenue when (or as) the entity satisfied the performance obligations. The Company implemented the transition using the modified retrospective method of transition. The funds are not earned on milestones that have not been reached per the contract. Based on the cut off treatment of the recognition of revenue per the milestones specific to the license agreements, the Company has determined that there are no adjustments in the value of the revenue recognized from these contracts. The Company has one revenue stream, which are the milestone payments of the license agreement with BioRay Pharmaceutical which is not earned or billed until the milestone per the agreement is met. During the nine months period ended December 31, 2022, no revenue was received.
Accounts receivable	Accounts receivables are carried at face value less any provisions for uncollectible amounts. Accounts receivable are receivables from a license agreement. No allowance for bad debt was considered necessary for the three and nine months ended December 31, 2022 and 2021, respectively. As of December 31, 2022, the Company did not have any accounts receivable.

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
	Dec. 31, 2022
RELATED PARTY TRANSACTIONS
Schedule of shares earned by related party	Officer and Director Initial Share Awards Under the Contracts Additional Shares Earned to Maintain Ownership Percentage Total Shares Earned President 1,028,910 8,890,269 9,919,179 Chief Financial Officer 617,346 4,677,723 5,295,069 Total 1,646,256 13,567,992 15,214,248
Schedule of future outstanding shares	Officer and Director Fiscal Year Annualized Compensation Being Paid President $ 250,000 Chief Financial Officer $ 180,000 Total $ 430,000

OPTIONS (Tables)

OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2022
OPTIONS
Schedule of Summary of stock options outstanding	Options Weighted Average Exercise Price Weighted Average Remaining Contract Life Number of Options Exercisable Intrinsic Value Outstanding at March 31, 2022 930,000 $ 0.34 3.80 930,000 $ - Granted 500,000 0.18 5.0 250,000 - Exercised - - - - - Outstanding at December 31, 2022 1,430,000 $ 0.28 4.06 1,180,000 $ 10,000

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2022
WARRANTS
Schedule of weighted average remaining life and intrinsic value of the warrants	Warrants Weighted Average Exercise Price Weighted Average Remaining Contract Life Intrinsic Value Outstanding at March 31, 2021 3,700,000 $ 0.15 2.00 $ - Granted - - - - Exercised - - - - Expired - - - - Outstanding at March 31, 2022 3,700,000 $ 0.15 1.35 $ - Granted 1,500,000 0.44 1.83 - Exercised (4,200,000 ) - - - Expired - - - - Outstanding as of December 31, 2022 1,000,000 $ 0.60 1.75 $ -

FAIR VALUE MEASUREMENTS AND D_2

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Tables)	9 Months Ended
	Dec. 31, 2022
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES
Schedule of change in fair value of derivative liabilities	Level 1 Level 2 Level 3 Fair value of derivative liability as of March 31, 2022 $ - $ - $ - Additions at fair value - - 1,706,612 Change in fair value of the derivative - - (634,118 ) Balance at December 31, 2022 $ - $ - $ 1,072,494
Schedule of estimated fair value drivative assumptions	Risk-free interest rate 4.73 % Expected life in years .67-.74 Dividend yield 0 % Expected volatility 135-163

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	9 Months Ended
	Dec. 31, 2022 shares
Initial Share Awards Under the Contracts	1,646,256
Additional Shares Earned to Maintain Ownership Percentage	13,567,992
Total Shares Earned	15,214,248
Chief Financial Officer [Member]
Additional Shares Earned to Maintain Ownership Percentage	4,677,723
Total Shares Earned	5,295,069
Initial Share Awards Under the Contracts	617,346
President Stock
Additional Shares Earned to Maintain Ownership Percentage	8,890,269
Total Shares Earned	9,919,179
Initial Share Awards Under the Contracts	1,028,910

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details 1)	9 Months Ended
	Dec. 31, 2022 USD ($)
Total	$ 430,000
Preferred Stock
Fiscal Year Annualized Compensation Being Paid	250,000
Chief Financial Officer [Member]
Fiscal Year Annualized Compensation Being Paid	$ 180,000

RELATED PARTY TRANSACTIONS (D_3

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Common stock shares issued for services, amount	$ 9,275	$ 60,000	$ 5,250
September 1, 2020 [Member]
Officers and directors employment agreement terms, description				Under the terms of the agreements the Company issued shares of common stock to the two senior officers equaling 18% of the outstanding shares of the Company as additional future shares are issued. The officers are entitled to additional future shares, so their aggregate ownership percentage remains at 18% of the future outstanding shares of the Company.
Two Officers And A Director
Common stock shares issued for services, shares				1,983,129
Common stock shares issued for services, amount				$ 514,740
Three Officers and Director [Member]
Common stock shares issued for services, shares					59,716
Common stock shares issued for services, amount					$ 568,719
Three Officers and Director [Member] | September 1, 2015 [Member]
Officers and directors employment agreement terms, description				the Company entered five-year employment contracts with three of its officers and directors. One of the officers and director resigned as of September 30, 2020. Under the terms of the agreements the Company issued shares of common stock to the officers and directors equaling 11% of the outstanding shares of the Company

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2022	Dec. 31, 2021	Mar. 31, 2022
Common stock shares, issued	122,046,172				122,046,172		111,313,175
Common stock shares issued for exercise of warrants					9,275
Common stock shares value for services, amount		$ 9,275	$ 60,000	$ 5,250
Common stock shares value for account payable, amount	$ 454,594	$ 101,973
Preferred Stock
Preferred stock converted into common stock					1,968,363	1,968,363
Preferred stock shares issued upon common stock, shares					54,130
Number of preferred stock share for conversion						54,130
Common stock shares issued for services					37,700	50,000
Common stock issue for conversion convertible note and interest					3,512,168
Common stock issue for conversion convertible note and interest Amount					$ 556,565
Conversion amount convertible note					550,000
Common stock issue amount interest					6,565
Common stock shares value for services, amount					9,275	$ 5,250
Four Entities [Member]
Common stock shares value for exercise of warrants, amount					$ 208,000
Common stock shares, issued	3,700,000				3,700,000
Common stock shares issued for exercise of warrants					4,200,000
Three Officers and Director [Member]
Common stock shares value for services, amount						$ 568,719
Common stock shares issued for services						59,716
Medical Director [Member]
Common stock shares value for services, amount					$ 60,000
Common stock shares issued for services					1,000,000
Two Officers and Director [Member]
Common stock shares issued for services					1,983,129
Common stock shares value for account payable, amount					$ 514,740
Director [Member]
Common stock shares issued for compensation, value						$ 23,332
Common stock shares issued for compensation, shares						307,010

OPTIONS (Details)

OPTIONS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2022
Options
Option, Beginning Balance	930,000
Option, granted	500,000
Option, ending Balance	1,430,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.34
Weighted average exercise price, Granted	0.18
Weighted average exercise price, Exercised	0
Weighted average exercise price, ending	$ 0.28	$ 0.34
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	3 years 9 months 18 days
Weighted Average Remaining Contract life, granted	5 years
Weighted Average Remaining Contract life, Ending	4 years 21 days
Number of option exercisable
Number of option exercisable, Beginning	930,000
Number of option exercisable, granted	250,000
Number of option exercisable, ending	1,180,000	930,000
Intrinsic value
Intrinsic value, Beginning	$ 0
Intrinsic value, Granted	0	$ 0
Intrinsic value, Exercised	0	$ 0
Intrinsic value ending	$ 10,000

OPTIONS (Details Narrative)

OPTIONS (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	Nov. 17, 2022	Dec. 31, 2022
OPTIONS
Company expensed	$ 5,727
Company issued options	500,000
Exercise price	$ 0.18
Stock options Contractual life	5 years
Vested options	250,000
Options fair value volatility	250%
Discount rate	4.35%
Amortization	$ 114,531
Weighted average remaining life and intrinsic value		4 years 21 days

WARRANTS (Details)

WARRANTS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2022	Mar. 31, 2022
Number of warrants
Outstanding warrants, Beginning	3,700,000	3,700,000
Outstanding warrants, granted	1,500,000
Outstanding warrants, Exercised	(4,200,000)
Outstanding warrants, Ending	1,000,000	3,700,000
Weighted average exercise price
Weighted average exercise price, Beginning	$ 0.15	$ 0.15
Weighted average exercise price, Granted	0.44	0
Weighted average exercise price, Exercised	0	0
Weighted average exercise price, Expired	0	0
Weighted average exercise price, Ending	$ 0.60	$ 0.15
Weighted Average Remaining Contract Life
Weighted Average Remaining Contract life, Beginning	1 year 4 months 6 days	2 years
Weighted Average Remaining Contract life, Granted	1 year 9 months 29 days
Weighted Average Remaining Contract life, Ending	1 year 9 months	1 year 4 months 6 days
Intrinsic value
Intrinsic value, Beginning	$ 0	$ 0
Intrinsic value, Granted	0	0
Intrinsic value, Exercised	0	0
Intrinsic value, Expired	0	0
Intrinsic value, Ending	$ 0	$ 0

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - USD ($)			1 Months Ended		9 Months Ended	12 Months Ended
	Sep. 02, 2022	Apr. 07, 2022	Nov. 17, 2022	Aug. 31, 2022	Dec. 31, 2022	Mar. 31, 2021
Deemed dividend from down round						$ 555,000
Warrant converted into common stock					3,700,000
Warrant converted into common stock amount					$ 148,000
Exercise price of warrants	$ 0.345	$ 0.08		$ 0.41
Warrants issued	250,000	500,000		750,000		3,700,000
Conversion price	$ 0.60	$ 0.12		$ 0.60		$ 0.15
Volatility rate	137%	132%		137%
Adjustments to additional paid-in capital, warrant issued	$ 2,484	$ 21,336		$ 9,902
Discount rate	3.47%	1.78%		3.50%
Fair value of warrant	$ 50,273	$ 26,000		$ 188,760
Volatility rate			250%
Warrant [Member]
Fair value of warrants						41%
value of warrants						$ 349,605
Total value of warrant						303,000
Fair value of common stock						$ 437,000
Minimum [Member]
Volatility rate					135%
Minimum [Member] | Warrant [Member]
Exercise price of warrants						$ 0.08
Discount rate						0.14%
Volatility rate						312.50%
Maximum [Member]
Volatility rate					163%
Maximum [Member] | Warrant [Member]
Exercise price of warrants						$ 0.11
Discount rate						0.16%
Volatility rate						314.49%
April 07, 2022 [Member]
Warrant converted into common stock					500,000
Warrant converted					500,000

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)

1 Months Ended

9 Months Ended

Sep. 09, 2022

Apr. 07, 2022

Aug. 10, 2021

Nov. 11, 2020

Nov. 17, 2022

Mar. 28, 2022

Aug. 16, 2021

Apr. 22, 2021

Apr. 20, 2021

Feb. 16, 2021

Oct. 28, 2020

Dec. 31, 2022

Sep. 27, 2022

Sep. 20, 2022

Sep. 02, 2022

Aug. 31, 2022

Mar. 31, 2022

Payment of Financing costs

$ 50,000

$ 35,000

$ 24,750

$ 41,400

Common stock

987,539

Convertible notes

$ 150,000

Interest

$ 100,000

Notes payable,principal

$ 275,000

Notes payable,interest

9,162

Notes payable,premium

42,624

Notes paid,total

$ 326,786

Debt conversion, principle balance

200,000

100,000

82,500

$ 138,000

Accrued interest

$ 9,973

$ 5,000

$ 8,250

Risk free interest rate

4.73%

Volatility rate

250%

Common share issued

122,046,172

111,313,175

Common share value

$ 122,046

$ 111,313

Debtenture 1

Risk free interest rate

3.50%

Volatility rate

137%

Expected life

1 year

Debtenture 2

Risk free interest rate

4.03%

Volatility rate

140%

Expected life

1 year

Debtenture 3

Risk free interest rate

3.98%

Volatility rate

141%

Expected life

1 year

August 31, 2022 [Member]

Conversion price, Description

Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value

Warrant expiry date

Aug. 30, 2024

Exercise price of warrant

$ 0.60

Convertible debentures with unrelated party

$ 1,500,000

Debt paid,first installement

$ 500,000

Debt paid,second installement

$ 500,000

Interest rate on convertible debenture

6%

Common stock issued for warrant purchase

750,000

Debt paid,third installement

$ 500,000

September 02, 2022 [Member]

Conversion price, Description

Debenture may be converted at the lesser of $0.30 per share or eighty percent (80%) of the lowest VWAP of the Company’s common stock for ten consecutive trading days immediately prior to the conversion date and carried an original discount of 3% of the debenture face value

Risk free interest rate

3.47%

Volatility rate

137%

Expected life

1 year

Warrant expiry date

Aug. 30, 2024

Exercise price of warrant

$ 0.60

Convertible debentures with unrelated party

$ 500,000

Debt paid,first installement

250,000

Debt paid,second installement

250,000

Interest rate on convertible debenture

6%

Common stock issued for warrant purchase

$ 250,000

Convertible Debt

Convertible debt

$ 400,000

Common share issued

2,524,629

Common share value

$ 406,566

Interest on convertible notes

6,566

Accrued interest

$ 1,100,000

Series A Convertible Preferred Stock [Member]

Debt conversion, principle balance

$ 25,000

$ 200,000

$ 7,500

$ 5,000

$ 10,000

Convertible debt

$ 275,000

$ 82,500

$ 100,000

$ 138,000

Conversion price, Description

Within 180 days of issuance, the note may be repaid at a premium of 115% of the face value of the note and 150% of the unconverted balance of the note after 180 days and prior to maturity. After 180 days the note may be converted into common stock of the Company at $0.075 per share or a 20% discount to the lowest VWAP (Volume- Weighted Average Pricing) price during the 10 days prior to conversion

Within 180 days of issuance the note may be repaid at an escalating premium up to 125% of the face value of the note. After 180 days the note was convertible into common stock of the Company at $0.06 per share or a 25% discount to the lowest trading price during the 10 days prior to conversion. The initial derivative was calculated using risk free interest of .05%, volatility of 132% and expected life of 0.50 years

After 180 days the note was convertible into common stock of the Company at a 35% discount to the lowest trading price during the 20 days prior to conversion

After 180 days the note was convertible into common stock of the Company at a 30% discount to the lowest trading price during the 15 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 213% and expected life of 1.00 years

After 180 days the note was convertible into common stock of the Company at $0.04 per share or a 30% discount to the VWAP during the 20 days prior to conversion. The initial derivative was calculated using risk free interest of .18%, volatility of 212% and expected life of .50 years

Risk free interest rate

0.05%

10%

10%

10%

Debt maturity date

Mar. 29, 2023

Feb. 10, 2022

Oct. 28, 2021

Feb. 16, 2022

Oct. 28, 2021

Interest rate

8%

10%

Volatility rate

132%

Expected life

6 months

FAIR VALUE MEASUREMENTS AND D_3

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details)	Sep. 30, 2022 USD ($)
Fair Value, Inputs, Level 1 [Member]
Fair value of derivative liability as of March 31, 2022	$ 0
Additions at fair value	0
Change in fair value of the derivative	0
Balance at December 31, 2022	0
Fair Value, Inputs, Level 2 [Member]
Fair value of derivative liability as of March 31, 2022	0
Additions at fair value	0
Change in fair value of the derivative	1,706,612
Balance at December 31, 2022	0
Fair Value, Inputs, Level 3 [Member]
Fair value of derivative liability as of March 31, 2022	0
Additions at fair value	0
Change in fair value of the derivative	(634,118)
Balance at December 31, 2022	$ 1,072,494

FAIR VALUE MEASUREMENTS AND D_4

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITIES (Details 1)	1 Months Ended	9 Months Ended
	Nov. 17, 2022	Dec. 31, 2022
Risk-free interest rate		4.73%
Dividend yield		0%
Volatility rate	250%
Maximum [Member]
Expected life in years		8 months 26 days
Volatility rate		163%
Minimum
Expected life in years		8 months 1 day
Volatility rate		135%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		1 Months Ended	9 Months Ended
	Mar. 09, 2020	Sep. 30, 2016	Dec. 31, 2022
Merger, description	Under the program, if an acquisition, merger or change in control is affected, 10% of the value of the transaction will be allocated to pay the expenses of the transaction including but not limited to legal, accounting, transfer fees and other miscellaneous expense. The balance of the fund after expenses will be allocated 20% to directors and 80% to officers and employees of the Company as allocated by the Chief Executive Officer and approved by the Board of Directors
Annual Maintenance			$ 325,000
Investment description		A contingent sales fee upon first commercial sale of a product of 1% of sales or $150,000 whichever is greater payable quarterly
First Phase I clinical trial [Member]
Future payments		$ 100,000
Annual maintenance fee		50,000
First Phase III clinical trial [Member]
Future payments		225,000
First BLA [Member]
Future payments		$ 225,000

LICENSE AGREEMENT (Details Narr

LICENSE AGREEMENT (Details Narrative) - BioRay Pharmaceutical Co LTD [Member]	9 Months Ended
	Dec. 31, 2022 USD ($)
Agreement description	Under the terms of the agreement the Company receives $250,000 upon signing of the agreement plus $750,000 with the start of the phase 1 clinical trials, which started in March 2021. In addition, the Company received $750,000 upon the enrollment of the 12th patient or the dosage level of 8.0 mg/kg, whichever was achieved first. Further payment of $2,500,000 will be received when the FDA approves the phase 2 clinical trials and $750,000 when the phase 2 clinical trials begin
Issuance of license agreement	$ 5,000,000
Royalty rate	9%
Net sales	20 years
Agreement	$ 250,000
Initial payment received	$ 1,750,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Feb. 09, 2023	Jan. 23, 2023	Dec. 31, 2022	Mar. 31, 2022
Common share issued			122,046,172	111,313,175
Subsequent Event
Common share issued	1,028,697	1,410,400
Conversion of convertible notes	$ 100,000	$ 100,000
Accrued interest	1,841	279
Interest principle	$ 101,841	$ 100,279